To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

January 6, 2015

New Clinical Trial!

Happy New Year to each of you!  2015 is starting off with a BANG with a focus on brain cancer patients and new treatment options for rGBM.  I am delighted to finally be able to BLOG about a new clinical trial that is recruiting at the Seton Brain & Spine Institute in Austin, TX and will soon be recruiting as well in Seattle, WA.  I am not at liberty to say more about the Seattle site at this time, but can talk further about this trial in Central Texas. 

Take a peek at this video to learn more about how this DEVICE works on Solid Tumors.  This device is now known as the “Nativis Voyager System”.  This video reflects how well it works and worked on canines.  The data from its use on canines was so incredibly positive, that it was used to get the human trials stared for recurrent GBM.  I have eagerly been sitting on the sidelines watching this technology, the canine clinical trial results and potential treatment for rGBM for the last 3 years. I am now DELIGHTED to see this potential new treatment for rGBM become available for brain cancer patients.  Check it out.

The Principal Investigator at Seton is Dr. Brain D. Vaillant.  The contact for this trial if you are interested in getting information and possibly participating is Heidi Herdon, RN, 513-324-7000, ext. 77713, This trial is noted as NCT02296580.  I am proud to say that Dr. Santosh Kesari, one of CEF’s Medial Advisory Board Members, is the Study Director for this study. 

If you are in the Central TX area and interested in enrolling in this trial, please contact Heidi Herdon and it you are in the Pacific Northwest and interested in learning more about this trial, including enrollment, please feel free to contact me directly at Dellann@ChrisElliottFund or at

2015 is already starting off with more and more treatment options for GBM patients.  Let’s keep the momentum going!!!


Dellann Elliott Mydland, Founder & President

The Chris Elliott Fund


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram